Malignant disease as an incidental finding at 18F-FDG-PET/CT scanning in patients with granulomatous lung disease
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F15%3A33156742" target="_blank" >RIV/61989592:15110/15:33156742 - isvavai.cz</a>
Výsledek na webu
<a href="http://dx.doi.org/10.1097/MNM.0000000000000274" target="_blank" >http://dx.doi.org/10.1097/MNM.0000000000000274</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1097/MNM.0000000000000274" target="_blank" >10.1097/MNM.0000000000000274</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Malignant disease as an incidental finding at 18F-FDG-PET/CT scanning in patients with granulomatous lung disease
Popis výsledku v původním jazyce
PURPOSE: Fluorine-18 fluorodeoxyglucose (18F-FDG)-PET/computed tomography (CT) is used for assessment of the extent and activity of disease in patients with inflammatory granulomatous lung disease, in particular sarcoidosis and tuberculosis. The aim of this retrospective analysis was to assess the value of 18F-FDG-PET/CT in the identification of previously unknown malignant disease during routine investigation of granulomatous lung disease. MATERIALS AND METHODS: From July 2008 to December 2013, a totalof 122 patients with tuberculosis (76 male and 46 female patients; age range 19.6-88.6 years, mean 52.8+-16.6 years) and 85 patients with sarcoidosis (46 male and 39 female patients; age range 17.8-76.5 years, mean 48.6+-13.8 years) underwent 18F-FDG-PET/CT. Reports were generated in consensus by both a nuclear medicine physician and a radiologist. Possibly malignant findings underwent biopsies and/or follow-up. Quantitative parameters (maximum standardized uptake value) were pooled and
Název v anglickém jazyce
Malignant disease as an incidental finding at 18F-FDG-PET/CT scanning in patients with granulomatous lung disease
Popis výsledku anglicky
PURPOSE: Fluorine-18 fluorodeoxyglucose (18F-FDG)-PET/computed tomography (CT) is used for assessment of the extent and activity of disease in patients with inflammatory granulomatous lung disease, in particular sarcoidosis and tuberculosis. The aim of this retrospective analysis was to assess the value of 18F-FDG-PET/CT in the identification of previously unknown malignant disease during routine investigation of granulomatous lung disease. MATERIALS AND METHODS: From July 2008 to December 2013, a totalof 122 patients with tuberculosis (76 male and 46 female patients; age range 19.6-88.6 years, mean 52.8+-16.6 years) and 85 patients with sarcoidosis (46 male and 39 female patients; age range 17.8-76.5 years, mean 48.6+-13.8 years) underwent 18F-FDG-PET/CT. Reports were generated in consensus by both a nuclear medicine physician and a radiologist. Possibly malignant findings underwent biopsies and/or follow-up. Quantitative parameters (maximum standardized uptake value) were pooled and
Klasifikace
Druh
J<sub>x</sub> - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)
CEP obor
FD - Onkologie a hematologie
OECD FORD obor
—
Návaznosti výsledku
Projekt
—
Návaznosti
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Ostatní
Rok uplatnění
2015
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
Nuclear Medicine Communications
ISSN
0143-3636
e-ISSN
—
Svazek periodika
36
Číslo periodika v rámci svazku
5
Stát vydavatele periodika
GB - Spojené království Velké Británie a Severního Irska
Počet stran výsledku
8
Strana od-do
430-437
Kód UT WoS článku
—
EID výsledku v databázi Scopus
—